coins with future Top Top stories

The negotiation between Myriad and United Health Insurance may be extended to the beginning of 2025, and the negotiation between Myriad Genetics and UnitedHealthcare on the genetic test of Myriad may continue until the beginning of 2025. Myriad reiterated its estimate of the financial impact of the United Health Insurance Company's updated medical policy in 2024.ADB lowered the growth forecast of developing economies in the Asia-Pacific region to maintain China's economic growth forecast. On December 11th, the Asian Development Bank issued the Asia Development Outlook 2024 (December Edition). According to the report, the development momentum in the Asia-Pacific region is steady, but as US President-elect Trump is about to take office, changes in his trade, finance and immigration policies may inhibit the development of the Asia-Pacific region and aggravate inflation. ADB lowered its growth forecast for developing economies in the Asia-Pacific region from the previous 5.0% to 4.9% in 2024, and from the previous 4.9% to 4.8% in 2025. China's economic growth is expected to remain at 4.8% and 4.5% in 2024 and 2025 respectively, which is the same as before.Guotai Junan's annual strategy for innovative drugs in 2025: innovative pharmaceutical companies have accelerated into the harvest period, and the valuation has been at a historical low in the past five years. Guotai Junan said that the centralized purchasing policy has become stable, mature and normalized, and the marginal impact has weakened. Innovative drugs have gained policy inclination in the medical insurance negotiation. In the past two years, the policy has continued to promote pharmaceutical innovation, and the top-level design and local supporting chain support the development of innovative drugs. Commercial insurance is expected to bring new growth momentum to China's pharmaceutical market, and the overall industry trend is upward. At present, the trend of innovative drug industry is improving, the supply continues to accelerate, and a number of domestic innovative drugs are approved soon, which is expected to drive a new round of heavy volume. At the same time, the commercialization has achieved remarkable results and has occupied a dominant position in some sub-sectors. Pharma's performance continued to differentiate, and innovative drugs and just-needed drugs performed well. Biotech commercialization continues to increase, per capita yield continues to increase, the node of turning losses is approaching, and innovation ushers in the harvest period. Horizontal comparison: compared with overseas peers, the overall valuation of domestic innovative pharmaceutical companies is in a historically low range; Vertical comparison: the valuation of SW- pharmaceutical biology and SW- chemical preparations is at a historical low in the past five years, and it is expected that the valuation of subsequent sectors will pick up.

Galaxy Securities: Macro-policies have increased the accumulation of positive factors in bank fundamentals. The china galaxy Securities Research Report said that the macro-policy upgrade has exceeded expectations and supported the growth of bank credit. Bank spreads are still under pressure, but the release of debt cost optimization results is expected to form support. Preventing and resolving the risk orientation in key areas remains unchanged, and the asset quality and risk expectation of banks are expected to benefit. The positive factors in the fundamentals of banking operations have accumulated, and we will continue to be optimistic about the allocation value of the banking sector and maintain the recommended rating. For individual stocks, ICBC, China Construction Bank, Postal Savings Bank, Jiangsu Bank and Changshu Bank are recommended.South Korea's exports increased by 12.4% and imports increased by 11.6% from December 1 to 10. South Korea's chip exports increased by 43% year-on-year from December 1 to 10.Huatai Securities: The policy overweight boosts consumption and is optimistic about the four main lines. Huatai Securities Research Report said that with the continuous efforts of promoting consumption policies, the large consumer sector ushered in the configuration window period and continued to be optimistic about the basic orientation and valuation repair of the consumer sector. It is suggested to pay attention to four main investment lines: 1) the rise of domestic products: the strength and brand power of domestic products in beauty care, home appliances, pets, textiles and clothing are constantly improving, occupying consumers' minds against the trend, and domestic products continue to lead; 2) Emotional consumption: the products on the supply side are continuously iterated, and the goods/services are built as a medium to convey emotional value, and the consumption on the demand side is superimposed to promote the continuous expansion of the tide play /IP economy; 3) New cost performance: The consumption concept of residents is becoming more and more rational, and the quality-price ratio has become the core of consumption decision-making. The new cost performance consumption focusing on "good but not expensive" is expected to continue to grow rapidly; 4) Consumption going to sea: Going to sea has become a necessary topic for consumer enterprises. Under the two-way catalysis of supply and demand, China enterprises are actively participating in global market competition and paying attention to brand/culture/service going to sea.

Japan's producer price in November increased by 0.3% month-on-month, and it is estimated to increase by 0.2%. Japan's producer price in November increased by 3.7% year-on-year, and it is estimated to increase by 3.4%.Analyst: There may be a RRR cut of 50 basis points to 100 basis points next year. Tan Yiming, chief fixed income analyst of Minsheng Securities, said that there may be a RRR cut of 50 basis points to 100 basis points next year, considering the supply pressure of government bonds, the restoration of credit supply and the provision of long-term stable low-cost funds for financial institutions.Nippon Steel's share price rose by 1.2% shortly after the opening on Wednesday, and it is basically flat at present. In the news, US President Biden plans to formally prevent Nippon Steel from acquiring American steel companies for $14.1 billion. American steel stocks plunged overnight, once falling by 22%, and finally closed down by 9.7%.